2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake E, Robertson D, Mendoza J, Lewin J, Everage N, Božin I, Lyons J, Mokliatchouk O, Bame E, Giuliani F. Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Advances In Therapy 2024, 1-18. PMID: 39570545, DOI: 10.1007/s12325-024-03047-w.Peer-Reviewed Original ResearchAbsolute lymphocyte countRelapsing-remitting MSEffect of dimethyl fumarateAnnualized relapse rateDisease-modifying therapiesAdverse eventsDimethyl fumarateCD8+ T cell compartmentMultiple sclerosisOlder patientsMedian absolute lymphocyte countOral disease-modifying therapyTreated with dimethyl fumarateSafety outcomesTreating relapsing MST cell compartmentPhase 3 studyResponse to disease-modifying therapiesIncidence of SAEsLymphocyte subset changesReal-world safetyTreatment discontinuationCD4+Immunophenotypic changesRelapse rate
2018
Effectiveness of alternative dose fingolimod for multiple sclerosis
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology Clinical Practice 2018, 8: 102-107. PMID: 29708225, PMCID: PMC5914753, DOI: 10.1212/cpj.0000000000000434.Peer-Reviewed Original ResearchProportion of patientsDaily doseMultiple sclerosisAlternate doseAdverse eventsDisease activityProfound lymphopeniaContrast-enhancing MRI lesionsAlternate dosingLiver function abnormalitiesClass IV evidenceDaily oral medicationContrast-enhancing lesionsBetter disease controlBreakthrough diseaseMRI lesionsRadiologic outcomesFunction abnormalitiesMost patientsOral medicationsRelapse rateFrequent dosingObservational studyFingolimodHigh risk